IP Library Granted Patent US 8,790,685
Granted Patent B2
US 8,790,685 · App. 13/293,484 · Granted Jul 29, 2014

Bioadhesive gel based on hydroxyethylcellulose

Inventor: Massimo Prini (Milan, IT)
Assignee: Mipharm S.p.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,790,685
App. No.
13/293,484
Granted
Jul 29, 2014
Kind
B2
Abstract

Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent.

Claims (5)

1. A method of delivering an active ingredient in the form of a bioadhesive gel composition to the mucosa of a subject in need thereof, said method comprising applying to an outer surface of said mucosa a composition consisting essentially of said active agent, glycerol and diethylene glycol monoethyl ether together with surfactants, preservatives and acidifiers, said composition formed into a gel and rendered bioadhesive by addition thereto of hydroxyethylcellulose.

2. The method according to claim 1 , wherein said mucosa is a vaginal mucosa of said subject.

3. A method of delivering an active ingredient in the form of a bioadhesive gel composition to the mucosa of a subject in need thereof, said method comprising applying to an outer surface of said mucosa a composition consisting essentially of more than 2% and less than 4% by weight of hydroxyethylcellulose, 25 to 90% by weight of water, 5 to 25% by weight of glycerol, 5 to 50% by weight of diethylene glycol monoethylether, 0.01 to 10% by weight of surfactant, 0.05 to 1% by weight preservative an 0.01 to 1% by weight of acidifier.

4. The method according to claim 1 , wherein said active ingredient consists essentially of one active agent selected from the group consisting of antifungals, antiseptics, local anaesthetics, antihistamines, anti-inflammatory agents, contraceptives, hormones and combinations thereof.

5. The method according to claim 4 , wherein said active ingredient is selected from the group consisting of econazole, miconazole, fluconazole, cyclopiroxolamine, nifuratel, chlorhexidine, ibuprofen, ketoprofen, naptoxen, benzydamine, benzalkonium chloride or other quaternary ammonium antiseptics and nonxynol-9.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2022
From: BPER BANCA S.P.A.; BANCO BPM S.P.A.
To: MIPHARM S.P.A.
Reel/Frame 059490/0370 →
PLEDGE Recorded Sep 12, 2017
From: MIPHARM S.P.A.
To: BANCA POPOLARE DI MILANO S.P.A.; BPER BANCA S.P.A.
Reel/Frame 043821/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2013
From: MITECH IDEA S.R.L.
To: MIPHARM S.P.A.
Reel/Frame 031136/0744 →
Priority Claims (1)
IT MI2003A1640 · Aug 8, 2003 · national
Continuity (2)
Continuation 10567890
Related Publication 20120083515A1 · Apr 5, 2012